via Neuroscience News
James Bibb, Ph.D., and colleagues have described a novel preclinical drug that could have the potential to combat depression, brain injury and diseases that impair cognition. The drug, which notably is brain-permeable, acts to inhibit the kinase enzyme Cdk5.
Cdk5 is a crucial regulator of signaling in brain neurons. Over three decades of study, it has been implicated in neuropsychiatric and neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease. Knocking out the enzyme in mice makes them resilient to stress, enhances their cognition, protects neurons from stroke and head trauma, and lessens neurodegeneration.
While inhibitors of Cdk5 could offer potential therapeutic benefits and new ways to study basic brain function, previous first- and second-generation anti-Cdk5 compounds largely get blocked at the blood-brain barrier that restricts movement of solutes from the blood to the central nervous system’s extracellular fluid. To date, no Cdk5 inhibitor has been approved to treat any neuropsychiatric or degenerative diseases.
Bibb and colleagues now report details of their anti-Cdk5, brain-permeable compound, 25-106. They also show that systemic administration of 25-106 alters neurobehavior in mice, reducing anxiety-like behavior.
“As perhaps the first robust systemic inhibitor, 25-106 represents an exciting and expandable and translatable pharmacological tool to study the function of Cdk5 activity in wild-type animals,” said Bibb, a professor in the University of Alabama at Birmingham Department of Surgery. “Achieving systemic applicability may be considered a step forward toward the testing of Cdk5 inhibitors to treat neuropsychiatric and neurodegenerative diseases. This provides a promising landscape for future studies to assess the effects of brain-permeable Cdk5 inhibitors to combat stress, anxiety, depression, addiction, cancer and neurodegeneration.”
The study, “Systemic administration of a brain permeable Cdk5 inhibitor alters neurobehavior,” is published in the journal Frontiers in Pharmacology.
In the paper, researchers describe synthesis of the aminopyrazole-based inhibitor, and they used molecular modeling to show that 25-106 appears to occupy the same hydrophobic binding pocket as the well-established Cdk5 inhibitor roscovitine.
They showed that 25-106 inhibited Cdk5 activity in a dose-dependent manner in brain striatal slices ex vivo, and that it also penetrated the brain after systemic administration in mice to inhibit Cdk5 in vivo. They measured the pharmacokinetic and pharmacodynamic parameters of 25-106 in blood plasma and the brains of mice, and the off-target distribution of 25-106 in the liver and kidneys.
Mice given systemic 25-106 showed modulated neurobehavior in the open field maze test and the tail suspension test, anxiolytic changes that have previously been linked to Cdk5 knockout mice.
They found that 25-106 is a non-selective inhibitor of both Cdk5 and another cyclin-dependent kinase, Cdk2, but note that very low levels of Cdk2 are found in the brain. However, any off-target or toxic effects of systemic inhibition of Cdk2 by 25-106 remain unknown.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Clear Aligner Therapy Market (New Report ) Revenue Growth is Making Marketplace Explosive During 2023-2029 |106 Pages Report
The Clear Aligner Therapy market has witnessed a growth from USD million in 2017 to USD million in 2022. With a CAGR of this market is estimated to reach USD million in 2029. Ask For Sample Report Who ...
- Global High Voltage Direct Current (HVDC) Cables Market 2023 [Latest Report] Size and Growth Difference Prediction till 2028 | 106 Pages Report
The High Voltage Direct Current (HVDC) Cables Market (2023-2028) Research Report | Updated Latest Report | Market ...
- Insights on the Compound Semiconductor Global Market to 2027 - Significant Growth in the Electronics Industry Fuels the Market
DUBLIN, Jan. 24, 2023 /PRNewswire/ -- The "Compound Semiconductor Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
- Global Compound Semiconductor Market Report 2022 to 2027: Industry Trends, Share, Size, Growth, Opportunities and Forecasts
The global compound semiconductor market size reached US$ 106.76 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 146.78 Billion by 2027, exhibiting a CAGR of 5.45% ...
- Boston 106, Toronto 104
Williams 7-13 7-8 25, Kornet 1-1 0-0 2, Brogdon 8-16 4-4 23, Pritchard 4-7 0-0 12. Totals 38-85 14-15 106. Anunoby 5-7 0-0 12, Siakam 14-23 1-2 29, Achiuwa 7-15 2-2 17, Barnes 4-9 0-0 10 ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”25-106 compound” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
- Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: Insight and Analysis on Over 30 Drugs and 20 Companies
DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of STAT3 has ...
- CRISPR Knockout Identifies New Biomarkers for PARP Inhibitor Resistance in Prostate Cancer
Two PARP inhibitors—olaparib (Lynparza) and rucaparib (Rubraca)—have been approved by the FDA to treat metastatic castration-resistant prostate cancer (mCRPC), and the data from the trials for ...
- A high-throughput screening assay for small molecule inhibitors of the antigen aminopeptidase ERAP1
This month's featured article, "A high-throughput MALDI-TOF MS biochemical screen for small molecule inhibitors of the antigen aminopeptidase ERAP1," by Müller, et al, presents a newly developed ...
- PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size 2023 With Presentation Outlook, Horizontal Viewpoint, Global View
Jan 27, 2023 (The Expresswire) -- The Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Size is Expected To Expand At A CAGR of 30.91% During The Forecast Period, Reaching USD 19311.04 ...
- MDM2 Inhibitor Breaks Through in Trial of Liposarcoma, Other Advanced Malignancies
Overall, the oral murine double minute-2 (MDM2) inhibitor milademetan produced a disease control rate (DCR) of 45.8% in 107 patients, including 58.5% in a subgroup with dedifferentiated ...
Go deeper with Google Headlines on:
[google_news title=”” keyword=”nano factory” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]